1. Academic Validation
  2. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1

  • Mol Cancer. 2014 May 6;13:103. doi: 10.1186/1476-4598-13-103.
Nathaniel Weygant Dongfeng Qu William L Berry Randal May Parthasarathy Chandrakesan Daniel B Owen Sripathi M Sureban Naushad Ali Ralf Janknecht Courtney W Houchen 1
Affiliations

Affiliation

  • 1 Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. [email protected].
Abstract

Background: Doublecortin-like kinase 1 (DCLK1) is emerging as a tumor specific stem cell marker in colorectal and pancreatic Cancer. Previous in vitro and in vivo studies have demonstrated the therapeutic effects of inhibiting DCLK1 with small interfering RNA (siRNA) as well as genetically targeting the DCLK1+ cell for deletion. However, the effects of inhibiting DCLK1 kinase activity have not been studied directly. Therefore, we assessed the effects of inhibiting DCLK1 kinase activity using the novel small molecule kinase inhibitor, LRRK2-IN-1, which demonstrates significant affinity for DCLK1.

Results: Here we report that LRRK2-IN-1 demonstrates potent anti-cancer activity including inhibition of Cancer cell proliferation, migration, and invasion as well as induction of Apoptosis and cell cycle arrest. Additionally we found that it regulates stemness, epithelial-mesenchymal transition, and oncogenic targets on the molecular level. Moreover, we show that LRRK2-IN-1 suppresses DCLK1 kinase activity and downstream DCLK1 effector c-Myc, and demonstrate that DCLK1 kinase activity is a significant factor in resistance to LRRK2-IN-1.

Conclusions: Given DCLK1's tumor stem cell marker status, a strong understanding of its biological role and interactions in gastrointestinal tumors may lead to discoveries that improve patient outcomes. The results of this study suggest that small molecule inhibitors of DCLK1 kinase should be further investigated as they may hold promise as anti-tumor stem cell drugs.

Figures
Products